morinidazole
ApprovedSmall molecule
Jiangsu Hansoh Pharmaceutical Co., Ltd.morinidazole is one of 37 small molecule programs targeting Pelvic Inflammatory Disease. It is currently in Approved.
2
Indications
2
Total Trials
0
Active Trials
36
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
64 competitors in Appendicitis
#DrugCompanyPhaseTrials
1Doribax
ShionogiApproved
Flagyl
DDePuy Orthopaedics
Approved
Invanz
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
MS Contin
HHikma Pharmaceuticals LLC
Approved
Piperacillin/tazobactam
PfizerApproved
Adrenaline
SSamson Clinical Operations Pty Ltd
Approved
Decadron
AAspen Global Incorporated
Approved
Marcaine
IInnocoll
Approved
Merrem
BB. Braun Medical Inc.
Approved
Ketalar
AAultman Health Foundation
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for morinidazole. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details